XNCR News and Press, Xencor Inc. From 01/11/22

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2022 corporate priorities and anticipated clinical development and research milestones. ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate in a pre-recorded fireside chat at the H.C. Wain...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced updated data from its Phase 1 dose-escalation study of plamotamab, a CD20 x CD3 bispecifi...

In a $480 million deal, Zenas, a Shanghai-Boston biopharma, acquired global rights to a bifunctional antibody from Xencor that targets CD19. Beijing's BeiGene closed on a 42-acre US site in the Princeton, NJ area where it will build a manufacturing center and house clinical R&D op...

Xencor (NASDAQ:XNCR) and Zenas BioPharma, a global biopharmaceutical company based in U.S. and China announce that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufacture and commercialize the investigational antibody obexelimab. Under the terms of the new ...

-- Vudalimab was generally well-tolerated; objective responses observed across multiple tumor types -- -- Confirmed partial responses observed in two of four evaluable castration-resistant prostate cancer patients with measurable disease -- -- Additional complete response observ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb ® bispecific antibod...

Xencor, Inc. (XNCR) Q3 2021 Earnings Conference Call November 8, 2021 4:30 PM ET Company Participants Charles Liles – Head-Corporate Communications and Investor Relations Bassil Dahiyat – President and Chief Executive Officer Allen Yang – Chief Medical Officer John Desjar...

Xencor (NASDAQ:XNCR): Q3 GAAP EPS of -$0.69 beats by $0.07. Revenue of $19.68M (-44.4% Y/Y) beats by $1.32M. Press Release For further details see: Xencor EPS beats by $0.07, beats on revenue

-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results f...